Experienced in Mediastinitis

Dr. Mezgebe Berhe

Infectious Disease | Internal Medicine
3409 Worth Street, Suite 710, 
Dallas, TX 
Offers Telehealth
32 Years of Experience
Experienced in Mediastinitis
3409 Worth Street, Suite 710, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mezgebe Berhe is an Infectious Disease specialist and an Internal Medicine provider in Dallas, Texas. Dr. Berhe has been practicing medicine for over 32 years and is rated as an Experienced provider by MediFind in the treatment of Mediastinitis. His top areas of expertise are Osteomyelitis, HIV/AIDS, Osteomyelitis in Children, and Myelitis.

His clinical research consists of co-authoring 19 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Addis Ababa University, 1993
Residency
Internal Medicine, St Barnabas Hospital
Specialties
Infectious Disease
Internal Medicine
Licenses
Specialist in TX
Board Certifications
American Board Of Internal Medicine
Fellowships
Infectious Disease, Medical College of Virginia Hospitals
Infectious Diseases, Medical College of Virginia
Hospital Affiliations
Hunt Regional Medical Center
Baylor University Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Primewell Health Services
  • HMO
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • POS
Scott and White Health
  • HMO
  • POS
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

North Texas Infectious Diseases Consultants, P.A.
3409 Worth Street, Suite 710, Dallas, TX 75246

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults
A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults
Enrollment Status: Terminated
Publish Date: June 26, 2024
Intervention Type: Drug
Study Drugs: GSK3640254, ABC/3TC, FTC/TAF, Dolutegravir
Study Phase: Phase 2
A Phase 3 Study of the Safety of Trogarzo® Administered as an Undiluted IV Push Over a Reduced Interval or as an Intramuscular Injection in Clinically Stable HIV-1 Infected Trogarzo® Experienced Patients and Healthy HIV-uninfected Volunteers
A Phase 3 Study of the Safety of Trogarzo® Administered as an Undiluted IV Push Over a Reduced Interval or as an Intramuscular Injection in Clinically Stable HIV-1 Infected Trogarzo® Experienced Patients and Healthy HIV-uninfected Volunteers
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Ibalizumab-uiyk
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Tenofovir alafenamide based regimen
Study Phase: Phase 3
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
Enrollment Status: Completed
Publish Date: January 20, 2023
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase 3b Multi-center, Open Label, Single Arm, 52-week Study, Evaluating the Feasibility, Efficacy and Safety of Rapid Test and Treat Intervention in Newly Diagnosed HIV-1 Infected Adults Using a Fixed Dose Combination of Dolutegravir Plus Lamivudine (DOVATO) as a First Line Regimen
A Phase 3b Multi-center, Open Label, Single Arm, 52-week Study, Evaluating the Feasibility, Efficacy and Safety of Rapid Test and Treat Intervention in Newly Diagnosed HIV-1 Infected Adults Using a Fixed Dose Combination of Dolutegravir Plus Lamivudine (DOVATO) as a First Line Regimen
Enrollment Status: Completed
Publish Date: October 21, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase Placebo-Controlled, Sequential Single Dose Escalation Study of the Safety, Pharmacokinetics, and Antiretroviral Activity of IVTMB-365 in HIV-1 Infected Participants
A Phase Placebo-Controlled, Sequential Single Dose Escalation Study of the Safety, Pharmacokinetics, and Antiretroviral Activity of IVTMB-365 in HIV-1 Infected Participants
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Biological
Study Drug: TMB-365
Study Phase: Phase 1
View 5 Less Clinical Trials

19 Total Publications

Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study.
Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: June 04, 2025
Similar Doctors
Advanced in Mediastinitis
Dr. Uriel S. Sandkovsky
Infectious Disease
Advanced in Mediastinitis
Dr. Uriel S. Sandkovsky
Infectious Disease

North Texas Infectious Diseases Consultants

3409 Worth St, Suite 710, 
Dallas, TX 
 (0.1 miles away)
214-823-2533
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Uriel Sandkovsky is an Infectious Disease provider in Dallas, Texas. Dr. Sandkovsky is rated as an Advanced provider by MediFind in the treatment of Mediastinitis. His top areas of expertise are Cytomegalovirus Infection, Cytomegalic Inclusion Disease, Mediastinitis, and Actinomycosis. Dr. Sandkovsky is currently accepting new patients.

Experienced in Mediastinitis
Dr. Michael E. Sebert
Pediatric Infectious Disease | Infectious Disease | Pediatrics
Experienced in Mediastinitis
Dr. Michael E. Sebert
Pediatric Infectious Disease | Infectious Disease | Pediatrics

University Of Texas Southwestern Medical Center At Dallas

1935 Medical District Dr, 
Dallas, TX 
 (3.7 miles away)
844-424-4537
Languages Spoken:
English
See accepted insurances

Michael Sebert is a Pediatric Infectious Disease specialist and an Infectious Disease provider in Dallas, Texas. Dr. Sebert is rated as an Advanced provider by MediFind in the treatment of Mediastinitis. His top areas of expertise are Bacterial Meningitis, Relapsing Fever, Typhus, and Staphylococcal Meningitis.

Experienced in Mediastinitis
Dr. Emma Dishner
Infectious Disease | Internal Medicine
Experienced in Mediastinitis
Dr. Emma Dishner
Infectious Disease | Internal Medicine

Texas Centers For Infectious Disease Associates

1025 College Ave, Ave, 
Fort Worth, TX 
 (32.5 miles away)
817-332-4060
Experience:
11+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Emma Dishner is an Infectious Disease specialist and an Internal Medicine provider in Fort Worth, Texas. Dr. Dishner has been practicing medicine for over 11 years and is rated as an Advanced provider by MediFind in the treatment of Mediastinitis. Her top areas of expertise are Herpes Simplex Encephalitis, Osteomyelitis, Methicillin-Resistant Staphylococcus Aureus (MRSA), and Pseudomonas Stutzeri Infections.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Berhe's expertise for a condition
ConditionClose
    View All 31 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile